Detalhe da pesquisa
1.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994196
2.
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Br J Haematol
; 202(3): 498-503, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37303189
3.
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Br J Haematol
; 196(6): 1337-1343, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34957541
4.
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
BMC Cancer
; 22(1): 1174, 2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376888
5.
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Br J Haematol
; 191(2): 231-242, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32394450
6.
The management of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 136-150, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38037886
7.
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 127-135, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932932
8.
Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
Br J Haematol
; 200(2): 150-159, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36278472
9.
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Haematologica
; 103(10): 1654-1661, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976746
10.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 16(13): 1295-305, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384238
11.
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Leukemia
; 37(2): 276-287, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36572750
12.
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Blood Adv
; 7(16): 4539-4549, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171402
13.
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.
Front Oncol
; 12: 840046, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35707351
14.
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
Haematologica
; 101(5): e182-4, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26819057
15.
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.
PLoS One
; 11(9): e0163291, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27669008
16.
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
Cancer Cell
; 19(1): 138-52, 2011 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21251617
17.
Targeting treatment in AML.
Hematology Am Soc Hematol Educ Program
; : 429-34, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18024661